Risperidone and the 5-HT<inf>2A</inf> Receptor Antagonist M100907 Improve Probabilistic Reversal Learning in BTBR T+tf/J Mice

Dionisio A. Amodeo, Joshua H. Jones, John A. Sweeney, Michael E. Ragozzino

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interactions with restricted interests and repetitive behaviors (RRBs). RRBs can severely limit daily living and be particularly stressful to family members. To date, there are limited options for treating this feature in ASD. Risperidone, an atypical antipsychotic, is approved to treat irritability in ASD, but less is known about whether it is effective in treating "higher order" RRBs, for example cognitive inflexibility. Risperidone also has multiple receptor targets in which only a subset may be procognitive and others induce cognitive impairment. 5HT<inf>2A</inf> receptor blockade represents one promising and more targeted approach, as various preclinical studies have shown that 5HT<inf>2A</inf> receptor antagonists improve cognition. The present study investigated whether risperidone and/or M100907, a 5HT<inf>2A</inf> receptor antagonist, improved probabilistic reversal learning performance in the BTBR T+tf/J (BTBR) mouse model of autism. The effects of these treatments were also investigated in C57BL/6J (B6) mice as a comparison strain. Using a spatial reversal learning test with 80/20 probabilistic feedback, similar to one in which ASD individuals exhibit impairments, both risperidone (0.125mg) and M100907 (0.01 and 0.1mg) improved reversal learning in BTBR mice. Risperidone (0.125mg) impaired reversal learning in B6 mice. Improvement in probabilistic reversal learning performance resulted from treatments enhancing the maintenance of the newly correct choice pattern. Because risperidone can lead to unwanted side effects, treatment with a specific 5HT<inf>2A</inf> receptor antagonist may improve cognitive flexibility in individuals with ASD while also minimizing unwanted side effects.

Original languageEnglish (US)
Pages (from-to)555-567
Number of pages13
JournalAutism Research
Volume7
Issue number5
DOIs
StatePublished - Oct 1 2014

Fingerprint

Reversal Learning
Serotonin 5-HT2 Receptor Antagonists
Receptor, Serotonin, 5-HT2A
Risperidone
Interpersonal Relations
Autistic Disorder
Cognition
Antipsychotic Agents
MDL 100907
Maintenance
Autism Spectrum Disorder

Keywords

  • Autism
  • BTBR
  • Cognitive flexibility
  • Reversal learning
  • Risperidone
  • Serotonin

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Genetics(clinical)

Cite this

Risperidone and the 5-HT<inf>2A</inf> Receptor Antagonist M100907 Improve Probabilistic Reversal Learning in BTBR T+tf/J Mice. / Amodeo, Dionisio A.; Jones, Joshua H.; Sweeney, John A.; Ragozzino, Michael E.

In: Autism Research, Vol. 7, No. 5, 01.10.2014, p. 555-567.

Research output: Contribution to journalArticle

Amodeo, Dionisio A. ; Jones, Joshua H. ; Sweeney, John A. ; Ragozzino, Michael E. / Risperidone and the 5-HT<inf>2A</inf> Receptor Antagonist M100907 Improve Probabilistic Reversal Learning in BTBR T+tf/J Mice. In: Autism Research. 2014 ; Vol. 7, No. 5. pp. 555-567.
@article{1924197d95be4ff584b992cf13bd91a3,
title = "Risperidone and the 5-HT2A Receptor Antagonist M100907 Improve Probabilistic Reversal Learning in BTBR T+tf/J Mice",
abstract = "Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interactions with restricted interests and repetitive behaviors (RRBs). RRBs can severely limit daily living and be particularly stressful to family members. To date, there are limited options for treating this feature in ASD. Risperidone, an atypical antipsychotic, is approved to treat irritability in ASD, but less is known about whether it is effective in treating {"}higher order{"} RRBs, for example cognitive inflexibility. Risperidone also has multiple receptor targets in which only a subset may be procognitive and others induce cognitive impairment. 5HT2A receptor blockade represents one promising and more targeted approach, as various preclinical studies have shown that 5HT2A receptor antagonists improve cognition. The present study investigated whether risperidone and/or M100907, a 5HT2A receptor antagonist, improved probabilistic reversal learning performance in the BTBR T+tf/J (BTBR) mouse model of autism. The effects of these treatments were also investigated in C57BL/6J (B6) mice as a comparison strain. Using a spatial reversal learning test with 80/20 probabilistic feedback, similar to one in which ASD individuals exhibit impairments, both risperidone (0.125mg) and M100907 (0.01 and 0.1mg) improved reversal learning in BTBR mice. Risperidone (0.125mg) impaired reversal learning in B6 mice. Improvement in probabilistic reversal learning performance resulted from treatments enhancing the maintenance of the newly correct choice pattern. Because risperidone can lead to unwanted side effects, treatment with a specific 5HT2A receptor antagonist may improve cognitive flexibility in individuals with ASD while also minimizing unwanted side effects.",
keywords = "Autism, BTBR, Cognitive flexibility, Reversal learning, Risperidone, Serotonin",
author = "Amodeo, {Dionisio A.} and Jones, {Joshua H.} and Sweeney, {John A.} and Ragozzino, {Michael E.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1002/aur.1395",
language = "English (US)",
volume = "7",
pages = "555--567",
journal = "Autism Research",
issn = "1939-3806",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Risperidone and the 5-HT2A Receptor Antagonist M100907 Improve Probabilistic Reversal Learning in BTBR T+tf/J Mice

AU - Amodeo, Dionisio A.

AU - Jones, Joshua H.

AU - Sweeney, John A.

AU - Ragozzino, Michael E.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interactions with restricted interests and repetitive behaviors (RRBs). RRBs can severely limit daily living and be particularly stressful to family members. To date, there are limited options for treating this feature in ASD. Risperidone, an atypical antipsychotic, is approved to treat irritability in ASD, but less is known about whether it is effective in treating "higher order" RRBs, for example cognitive inflexibility. Risperidone also has multiple receptor targets in which only a subset may be procognitive and others induce cognitive impairment. 5HT2A receptor blockade represents one promising and more targeted approach, as various preclinical studies have shown that 5HT2A receptor antagonists improve cognition. The present study investigated whether risperidone and/or M100907, a 5HT2A receptor antagonist, improved probabilistic reversal learning performance in the BTBR T+tf/J (BTBR) mouse model of autism. The effects of these treatments were also investigated in C57BL/6J (B6) mice as a comparison strain. Using a spatial reversal learning test with 80/20 probabilistic feedback, similar to one in which ASD individuals exhibit impairments, both risperidone (0.125mg) and M100907 (0.01 and 0.1mg) improved reversal learning in BTBR mice. Risperidone (0.125mg) impaired reversal learning in B6 mice. Improvement in probabilistic reversal learning performance resulted from treatments enhancing the maintenance of the newly correct choice pattern. Because risperidone can lead to unwanted side effects, treatment with a specific 5HT2A receptor antagonist may improve cognitive flexibility in individuals with ASD while also minimizing unwanted side effects.

AB - Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interactions with restricted interests and repetitive behaviors (RRBs). RRBs can severely limit daily living and be particularly stressful to family members. To date, there are limited options for treating this feature in ASD. Risperidone, an atypical antipsychotic, is approved to treat irritability in ASD, but less is known about whether it is effective in treating "higher order" RRBs, for example cognitive inflexibility. Risperidone also has multiple receptor targets in which only a subset may be procognitive and others induce cognitive impairment. 5HT2A receptor blockade represents one promising and more targeted approach, as various preclinical studies have shown that 5HT2A receptor antagonists improve cognition. The present study investigated whether risperidone and/or M100907, a 5HT2A receptor antagonist, improved probabilistic reversal learning performance in the BTBR T+tf/J (BTBR) mouse model of autism. The effects of these treatments were also investigated in C57BL/6J (B6) mice as a comparison strain. Using a spatial reversal learning test with 80/20 probabilistic feedback, similar to one in which ASD individuals exhibit impairments, both risperidone (0.125mg) and M100907 (0.01 and 0.1mg) improved reversal learning in BTBR mice. Risperidone (0.125mg) impaired reversal learning in B6 mice. Improvement in probabilistic reversal learning performance resulted from treatments enhancing the maintenance of the newly correct choice pattern. Because risperidone can lead to unwanted side effects, treatment with a specific 5HT2A receptor antagonist may improve cognitive flexibility in individuals with ASD while also minimizing unwanted side effects.

KW - Autism

KW - BTBR

KW - Cognitive flexibility

KW - Reversal learning

KW - Risperidone

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=84939260745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939260745&partnerID=8YFLogxK

U2 - 10.1002/aur.1395

DO - 10.1002/aur.1395

M3 - Article

C2 - 24894823

AN - SCOPUS:84939260745

VL - 7

SP - 555

EP - 567

JO - Autism Research

JF - Autism Research

SN - 1939-3806

IS - 5

ER -